… of erlotinib (ETB), a potent anticancer drug, in spiked human … sensitive technique for
determination of drug in plasma [9–12]. … binding ability of ETB with bovine serum albumin [13], it …

… of erlotinib in human plasma was … –erlotinib) 17 and 97.1% ± 0.85% (European Medicines
Agency report). In vitro studies showed that erlotinib was predominantly bound to albumin and …

… on the enhanced plasma exposure and the reduced elimination of erlotinib. Due to increased
exposure to erlotinib, there is a greater risk of adverse drug reactions to this drug. On the …

… of erlotinib conjugated magnetic nanoparticles (erlotinib-MNPs) compared to erlotinib was
… In this paper, MNPs were conjugated to erlotinib drug and its interaction with A549 cells was …

… In this study, a therapeutic drug monitoring (TDM) of erlotinib in pancreatic cancer patients
was performed over 50 weeks to reveal possible alterations in erlotinib plasma concentrations…

… vandetanib with human serum albumin, and proposed that the introduction of the drug affects
the … kinase inhibitor erlotinib with BSA [6], proposed that the presence of the drug affects the …

… increase plasma exposure to erlotinib. Given the maximum tolerated dose of erlotinib
used in clinical practice, we recommend that erlotinib be taken under conditions of fasting. …

… ) are the most relevant drug carriers in blood plasma. Since … acute-phase protein human
serum albumin (HSA, 600 M) is … Similarly to gefitinib, erlotinib (Tarceva ) also specifically targets …

… This finding is consistent with the observed mean erlotinib plasma C max in patients in this
study (1 µmol/l) in comparison with the in-vitro K i of 7.5 µmol/l. Similar to our results, gefitinib, …

… Subsequent absorption, around 93% protein binding is shown by erlotinib to plasma
albumin and alpha-1 acid glycoprotein with 232 L apparent volume of distribution [32, 43]. …